X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ASTRAZENECA PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. ASTRAZENECA PHARMA FRESENIUS KABI ONCO./
ASTRAZENECA PHARMA
 
P/E (TTM) x 22.1 91.2 24.3% View Chart
P/BV x 3.1 13.0 24.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ASTRAZENECA PHARMA
Mar-14
FRESENIUS KABI ONCO./
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1761,285 13.7%   
Low Rs79634 12.4%   
Sales per share (Unadj.) Rs37.7189.6 19.9%  
Earnings per share (Unadj.) Rs5.1-0.2 -2,501.6%  
Cash flow per share (Unadj.) Rs6.73.8 174.9%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.568.6 62.0%  
Shares outstanding (eoy) m158.2325.00 632.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.45.1 66.7%   
Avg P/E ratio x25.0-4,712.7 -0.5%  
P/CF ratio (eoy) x18.9249.6 7.6%  
Price / Book Value ratio x3.014.0 21.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,13523,988 83.9%   
No. of employees `0001.21.6 73.9%   
Total wages/salary Rs m7031,605 43.8%   
Avg. sales/employee Rs Th5,176.23,040.2 170.3%   
Avg. wages/employee Rs Th610.41,029.2 59.3%   
Avg. net profit/employee Rs Th699.6-3.3 -21,426.8%   
INCOME DATA
Net Sales Rs m5,9634,740 125.8%  
Other income Rs m1892 19.5%   
Total revenues Rs m5,9814,832 123.8%   
Gross profit Rs m1,430-130 -1,101.8%  
Depreciation Rs m258101 254.8%   
Interest Rs m-260-   
Profit before tax Rs m1,216-139 -875.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68139 -49.0%   
Tax Rs m3425 6,723.0%   
Profit after tax Rs m806-5 -15,833.0%  
Gross profit margin %24.0-2.7 -875.7%  
Effective tax rate %28.1-3.7 -767.8%   
Net profit margin %13.5-0.1 -12,584.9%  
BALANCE SHEET DATA
Current assets Rs m5,1022,726 187.1%   
Current liabilities Rs m2,3852,435 98.0%   
Net working cap to sales %45.66.1 740.9%  
Current ratio x2.11.1 191.0%  
Inventory Days Days15074 203.4%  
Debtors Days Days11341 277.9%  
Net fixed assets Rs m5,1481,035 497.3%   
Share capital Rs m15850 316.4%   
"Free" reserves Rs m6,556942 695.6%   
Net worth Rs m6,7321,716 392.3%   
Long term debt Rs m9520-   
Total assets Rs m10,3884,156 250.0%  
Interest coverage x-45.8NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.1 50.3%   
Return on assets %7.5-0.1 -6,130.1%  
Return on equity %12.0-0.3 -4,036.0%  
Return on capital %14.60-  
Exports to sales %74.55.7 1,306.3%   
Imports to sales %24.86.5 383.4%   
Exports (fob) Rs m4,441270 1,643.4%   
Imports (cif) Rs m1,477306 482.3%   
Fx inflow Rs m5,298375 1,414.2%   
Fx outflow Rs m1,772470 376.9%   
Net fx Rs m3,525-96 -3,689.6%   
CASH FLOW
From Operations Rs m1,274-8 -15,729.6%  
From Investments Rs m-1,204-146 826.5%  
From Financial Activity Rs m-196862 -22.7%  
Net Cashflow Rs m-126709 -17.8%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 75.0 108.0%  
Indian inst/Mut Fund % 0.3 0.3 100.0%  
FIIs % 9.6 15.7 61.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 9.1 100.0%  
Shareholders   42,599 12,856 331.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; Tata Stocks in Focus(09:30 am)

Asian stock indices are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.13% while the Hang Seng is down 0.54%. The Shanghai Composite is trading down by 0.02%.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS